A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Clinical trial NCT05100862 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05100862
- Sponsor
- BeOne Medicines
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-10
- Primary completion
- 2028-07-01
- Enrollment
- 799
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.